ライフサイエンスコーパス: cancer xenograft

1 ayed good in vivo efficacy in a human breast cancer xenograft.

2 r in the castration-recurrent human prostate cancer xenograft.

3 from the castration-recurrent CWR22 prostate cancer xenograft.

4 GFR activation was also seen in a colorectal cancer xenograft.

5 HER3 overexpressing H441 non-small cell lung cancer xenograft.

6 aded with survivin siRNA, inhibited prostate cancer xenograft.

7 esicles inhibited patient-derived colorectal cancer xenograft.

8 e treatment on nude mice bearing HT-29 colon cancer xenograft.

9 in tumor pO2 in highly vascular 786-0 renal cancer xenografts.

10 cultured gastric cancer cells and in gastric cancer xenografts.

11 aring high EpCAM-expressing HT-29 colorectal cancer xenografts.

12 umumab, and injected into mice bearing colon cancer xenografts.

13 een chemotherapy cycles, using human bladder cancer xenografts.

14 opyruvate impaired the growth of endometrial cancer xenografts.

15 ncers and inhibited tumor outgrowth of basal cancer xenografts.

16 ction in tumor volumes in vivo in pancreatic cancer xenografts.

17 LIC4 in stromal cells enhances the growth of cancer xenografts.

18 high MET-expressing H441 non-small cell lung cancer xenografts.

19 bition in prodrug-treated mice bearing human cancer xenografts.

20 tive localization of phage to human prostate cancer xenografts.

21 ng A33 antigen-expressing, SW1222 colorectal cancer xenografts.

22 sis, and reduced tumor growth in established cancer xenografts.

23 xil(R) administration in A2780 human ovarian cancer xenografts.

24 utaneous syngeneic melanoma and human breast cancer xenografts.

25 cell compartment of primary human pancreatic cancer xenografts.

26 to exert antitumor effects against prostate cancer xenografts.

27 de were assessed in several human epithelial cancer xenografts.

28 nderexpressed in CD44(+) cells from prostate cancer xenografts.

29 ich vary during tumor growth in subcutaneous cancer xenografts.

30 ing the uterus or enhancing growth of breast cancer xenografts.

31 nitoring of VEGFR2 expression in human colon cancer xenografts.

32 ion of sizable human lymphoma and pancreatic cancer xenografts.

33 y in androgen deprivation-resistant prostate cancer xenografts.

34 in SCID mice bearing MDA-MB231 human breast cancer xenografts.

35 in nude mice bearing CaPan1 human pancreatic cancer xenografts.

36 e bearing U87MG glioma and MDA-MB-435 breast cancer xenografts.

37 e collection of freshly generated pancreatic cancer xenografts.

38 th factor receptor 2-expressing human breast cancer xenografts.

39 ronously during the growth of human prostate cancer xenografts.

40 mmunodeficient rat model supports human lung cancer xenografts.

41 ssion, and angiogenesis in the human bladder cancer xenografts.

42 he in vivo growth of RNF43-mutant pancreatic cancer xenografts.

43 doxorubicin (PLD) in vivo, utilizing ovarian cancer xenografts.

44 sociated macrophages and the growth of colon cancer xenografts.

45 estrogen-independent MDA-MB-231 human breast cancer xenografts.

46 as well as local invasion and metastasis of cancer xenografts.

47 reduces tumor growth in patient-derived lung cancer xenografts.

48 o in blood, and for DCE MR imaging of breast cancer xenografts.

49 rowth were also observed in mouse colorectal cancer xenografts.

50 major regressions of pancreatic and stomach cancer xenografts.

51 lung, and esophageal squamous cell carcinoma cancer xenografts.

52 9 (colorectal cancer) and MDA-MB-231 (breast cancer) xenografts.

53 injection, P = 0.006) and the CWR22 prostate cancer xenografts (0.34 +/- 0.08 vs. 0.098 +/- 0.033 %ID

54 nd treatment-resistant HT29 human colorectal cancer xenografts 24 h after a single dose of conatumuma

55 nd treatment-resistant HT29 human colorectal cancer xenografts 24 h after a single dose of conatumuma

56 In cancer xenografts, (99m)Tc-TCP-1 radioactivity (%ID/g) w

57 d in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and H520) in mice and in

58 tion, and in vivo growth of human pancreatic cancer xenografts after Bmi1 silencing.

59 uptake was also observed in NCI-N87 gastric cancer xenografts, allowing tumor detection as early as

60 iral vectors to target chk in a human breast cancer xenograft and noninvasive MRS detection of this t

61 ability while preserving efficacy in ovarian cancer xenograft and patient-derived xenograft models.

62 tes was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmunoc

63 ced tumor growth in both prostate and breast cancer xenografts and doubled the median survival time o

64 ression and prolonged survival in pancreatic cancer xenografts and genetic mouse models.

65 triptase in vivo was measured in human colon cancer xenografts and in a patient-derived xenograft mod

66 ion of Duox expression in vivo in pancreatic cancer xenografts and in patients with chronic pancreati

67 an prostate epithelial cells, human prostate cancer xenografts and mouse prostate glands.

68 Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in

69 tenuated the growth of patient-derived colon cancer xenografts and reduced tumor blood flow.

70 The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy eff

71 restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancer

72 tient cancer tissues, patient-derived breast cancer xenografts, and cancer cell lines.

73 tumor growth in mice bearing human prostate cancer xenografts, and heparin derivatives specifically

74 kPa, G (l) = 6.0 +/- 0.2 kPa, n = 6) breast cancer xenografts, and luc-PANC1 (G (d) = 6.9 +/- 0.3 kP

75 ce bearing androgen-dependent CWR22 prostate cancer xenografts, and male and female athymic nude mice

76 profoundly reduced growth of MM and ovarian cancer xenografts, and oral RA190 treatment retarded HPV

77 BBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastroi

78 kPa, G (l) = 2.2 +/- 0.1 kPa, n = 7) breast cancer xenografts, and Th-MYCN neuroblastomas (G (d) = 3

79 ureteral obstruction and metastasis of human cancer xenografts are suppressed by administration of se

80 vivo antigen-specific targeting of prostate cancer xenografts as early as 1 h after injection.

81 +/- 0.15, P < .001) of mice with esophageal cancer xenografts, as well as the smallest relative tumo

82 +/- 0.15, P < .001) of mice with esophageal cancer xenografts, as well as the smallest relative tumo

83 stablished HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectiv

84 of hematological and triple negative breast cancer xenografts at well-tolerated doses.

85 [(18)F]-FLT-PET was conducted in human cancer xenograft-bearing mice.

86 (small, medium, large) in three subcutaneous cancer xenografts (breast, ovarian, pancreatic cancer) i

87 ripheral blood of SCID mice bearing prostate cancer xenografts but not in tumor-bearing mice treated

88 ce inhibited the growth of SW480 human colon cancer xenografts by 58% compared with control (P < 0.01

89 vestigation of EpoR expression in human lung cancer xenografts by fluorescence-mediated tomography.

90 ABL inhibitor nilotinib in MDA-MB-468 breast cancer xenografts) caused changes in the tumor epithelia

91 t cancer cells, mesothelioma cells, and lung cancer xenograft cells.

92 retomes in triple negative MDA-MB-231 breast cancer xenografts compared to ER-positive MCF-7 xenograf

93 iangiogenic treatment effects in human colon cancer xenografts compared with ex vivo reference standa

94 , G (l) = 6.2 +/- 0.2 kPa, n = 7) pancreatic cancer xenografts, compared with tumors associated with

95 es in mice with breast, lung, and esophageal cancer xenografts consistently showed enhanced (89)Zr-AC

96 inistration of chemotherapy to human bladder cancer xenografts could trigger a wound-healing response

97 mirrors its compartmentalization in prostate cancer xenograft cultures as result of mutation-rendered

98 Prostate cancer xenografts derived from castration-resistant tumo

99 BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient wi

100 miRNAs originating from human prostate cancer xenografts enter the circulation, are readily mea

101 In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR

102 nanoparticles accumulated in a human ovarian cancer xenograft following intravenous injection is demo

103 8 (HER2-negative/HER3-positive) human breast cancer xenografts from 4.4 +/- 0.9 to 2.6 +/- 0.5 %ID/g

104 (HER2-positive/HER3-negative) human ovarian cancer xenografts from 7.0 +/- 1.2 to 2.6 +/- 1.5 %ID/g

105 f palpable tumors in patient-derived ovarian cancer xenografts from ascites (PDXa).

106 SCID mice with human PC3 prostate cancer xenografts (Group IV, n=5) were also imaged with

107 restoration of NMI expression reduced breast cancer xenograft growth and downregulated Wnt and TGFbet

108 nd uterine enlargement and MCF-7 cell breast cancer xenograft growth in vivo were stimulated by estra

109 cancer cell proliferation and retards colon cancer xenograft growth.

110 Human non-small cell lung cancer xenografts (H460) in athymic rats were imaged wit

111 significantly inhibited the growth of human cancer xenografts harboring activated FGFR2 signaling.

112 ose per gram [%ID/g]) in BT-474 human breast cancer xenografts (HER2-positive/HER3-positive) occurred

113 biomarkers to identify radioresistant breast cancer xenografts highly amenable to sensitization by co

114 Different bladder cancer xenografts, however, demonstrate differential sen

115 siologic characteristics of a human prostate cancer xenograft implanted orthotopically in the prostat

116 vely blocks tumor growth in human pancreatic cancer xenografts in a nude mouse model.

117 gates gave high-contrast PET images of colon cancer xenografts in athymic mice.

118 f IGFBP-3R in vivo using prostate and breast cancer xenografts in athymic nude mice.

119 ble to assess tumor perfusion in human colon cancer xenografts in mice and allows for assessment of e

120 ) to VEGFR2 was tested in human LS174T colon cancer xenografts in mice with a 40-MHz ultrasonographic

121 ressed growth of the subcutaneous pancreatic cancer xenografts in mice with minimized side effects.

122 Using cell-based tests, orthotopic breast cancer xenografts in mice, and genome-wide transcription

123 t in vivo by inhibiting the growth of breast cancer xenografts in mice, which was associated with pro

124 icle as well as PLGA-PEG-NP into human colon cancer xenografts in mice.

125 tive NCI-N87 and HER2-negative MKN74 gastric cancer xenografts in mice.

126 rceptin) in HER2-overexpressing human breast cancer xenografts in mice.

127 growth, progression, and metastasis of lung cancer xenografts in mice.

128 t pitavastatin induces regression of ovarian cancer xenografts in mice.

129 monstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific

130 ibe a novel in vivo model using human breast cancer xenografts in NOD scid gamma (NSG) mice; in this

131 In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy

132 ceptor kinase-expressing non-small cell lung cancer xenografts in rodents.

133 state cancer and the suppression of prostate cancer xenografts in SCID mice by forced expression of G

134 ed and selective activity against human lung cancer xenografts in vivo via the intravenous and oral r

135 Treatment of breast cancer xenografts in vivo with the retinoid fenretinide

136 d in growth restriction of orthotopic breast cancer xenografts in vivo.

137 y formation in vitro, and growth of prostate cancer xenografts in vivo.

138 l lines in vitro as well as in PC-3 prostate cancer xenografts in vivo.

139 he growth and proliferation rate of prostate cancer xenografts in vivo.

140 le growth inhibition and apoptosis in breast cancer xenografts in vivo.

141 of HER-2/neu-positive BT474-SC1 human breast cancer xenografts in vivo.

142 However, data from colorectal cancer xenografts indicated that (64)Cu-ATSM may not be

143 hRNA-mediated silencing of RON in pancreatic cancer xenografts inhibited their growth, primarily by i

144 g bevacizumab therapy in two types of breast cancer xenografts (KPL-4 and MDA-MB-468).

145 delivery for VEGF knockdown in a human lung cancer xenograft, leading to enhanced tumour suppressive

146 Human prostate cancer xenografts (LNCaP) were transplanted subcutaneous

147 o anticancer activity against a human breast cancer xenograft (MDA-MB-435) in athymic nude mice.

148 Small-animal PET was performed in 3 human cancer xenograft mice models, expressing different level

149 In PTEN-null prostate cancer xenografts, mLST8 mutations disrupting the mTOR i

150 In this breast cancer xenograft model (MDA-MB-436 cells), analysis of d

151 imary tumors and lung metastases in a breast cancer xenograft model as well as extravasation followin

152 tumor regression in the H146 small-cell lung cancer xenograft model at a well-tolerated dose schedule

153 election RNAi screening using a human breast cancer xenograft model at an orthotopic site in the mous

154 tion with temozolomide and in an MX-1 breast cancer xenograft model both as a single agent and in com

155 evaluated in a human PSCA-positive prostate cancer xenograft model by sequential immuno-PET and opti

156 es performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzu

157 mor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as

158 aft results from the MDA-MB-468 human breast cancer xenograft model for compound 18 support the inves

159 ds in reducing tumorigenesis in a colorectal cancer xenograft model in athymic nude mice.

160 ith temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carbop

161 tient-derived CXCR7-expressing head and neck cancer xenograft model in nude mice, tumor growth was in

162 al drug-loaded micelles or free cisplatin in cancer xenograft model in vivo.

163 duces cooperative antitumor activity in lung cancer xenograft model in vivo.

164 ce to 5-FU-induced apoptosis in a colorectal cancer xenograft model of 5-FU monotherapy.

165 In the nonsmall cell lung cancer xenograft model studied, a linear correlation bet

166 re, inducible knockdown of SCD1 in a bladder cancer xenograft model substantially inhibited tumor pro

167 ivo during the progression of a human breast cancer xenograft model was guided by a bi-phasic host cy

168 th Tsc2(+/) (-) mice and a TSC1-null bladder cancer xenograft model with a CDK7 inhibitor showed mark

169 In a human epithelial cancer xenograft model, Ad14P1 showed more efficient vir

170 In the CWR-22-BMSLD1 human prostate cancer xenograft model, BMS-641988 showed increased effi

171 one at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher

172 In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defe

173 nd negligible deleterious effects in a colon cancer xenograft model, giving rise to the possibility o

174 In a human breast cancer xenograft model, miR-221-overexpressing MDA-MB-23

175 uciferase-expressing ES-2 (ES-2-luc) ovarian cancer xenograft model, single i.p. injections of g-E an

176 In a human colon cancer xenograft model, the primary tumor was surrounded

177 idazole PET imaging in a non-small cell lung cancer xenograft model, we showed that metformin may act

178 h castration in a hormone-sensitive prostate cancer xenograft model.

179 ere, we examined this question in an ovarian cancer xenograft model.

180 r activity against the MIA PaCa-2 pancreatic cancer xenograft model.

181 ed tumor regression in the MDA-MB-231 breast cancer xenograft model.

182 , and inhibition of tumor growth in a breast cancer xenograft model.

183 ition effects using an MDA-MB-231/Luc breast cancer xenograft model.

184 trate this effect using a human PC3 prostate cancer xenograft model.

185 ted TFRC expression in a MYC-driven prostate cancer xenograft model.

186 -TOPK-032 suppressed tumor growth in a colon cancer xenograft model.

187 h when dosed orally in the MDA-MB-231 breast cancer xenograft model.

188 o and inhibition of tumor growth in a breast cancer xenograft model.

189 istered orally in a human BT474 human breast cancer xenograft model.

190 s tumor growth when dosed orally in a breast cancer xenograft model.

191 prolonged survival in the MDA-MB-231 breast cancer xenograft model.

192 n athymic nude mouse MDA-MB-231 human breast cancer xenograft model.

193 and activity in vivo in an SW620 colorectal cancer xenograft model.

194 obes (ChL6 is chimeric L6) in a human breast cancer xenograft model.

195 e GR positive HCC1806 triple negative breast cancer xenograft model.

196 efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.

197 inistration of Onc.Ad in an HER2(+) prostate cancer xenograft model.

198 lso mediated improved survival in an ovarian cancer xenograft model.

199 when intratumorally injected into a prostate cancer xenograft model.

200 g, motility, and tumor formation in a breast cancer xenograft model; however, its mechanism of action

201 curative efficacy in human melanoma and lung cancer xenograft models and are promising candidates for

202 in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SM

203 oad spectrum tumour growth stasis in ovarian cancer xenograft models during continuous chronic treatm

204 ession levels of uPAR across different human cancer xenograft models in mice and to illustrate the cl

205 bute to cancer progression in human prostate cancer xenograft models in mice following castration.

206 s were further evaluated in gastric and lung cancer xenograft models in mice.

207 ukemia and MDA-MB-231 triple-negative breast cancer xenograft models in mice.

208 f radiation therapy and intetumumab in human cancer xenograft models in nude rats to assess effects o

209 es tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung can

210 nificant antitumor effects in multiple human cancer xenograft models led to the selection of 28g (MPC

211 luminescence and NIR fluorescence imaging of cancer xenograft models represents a powerful in vivo st

212 ich exhibited strong monotherapy efficacy in cancer xenograft models that carry certain DNA damage re

213 itatively measured in vivo in human prostate cancer xenograft models through PET imaging with a fully

214 noninvasively detect active uPA in prostate cancer xenograft models using optical and single-photon

215 For in vivo PET studies, two human lung cancer xenograft models were established using MET-posit

216 acy and bioavailability in ovarian and colon cancer xenograft models when evaluated for dose-ranging

217 hese effects were confirmed in vivo in colon cancer xenograft models with demonstrations that IGF-I r

218 In two colorectal cancer xenograft models, displaying differential sensiti

219 In breast cancer xenograft models, replacement of endogenous ALDH1

220 hemical findings are recapitulated in breast cancer xenograft models.

221 MDA-MB-436 and SUM149 triple negative breast cancer xenograft models.

222 sed metastasis in MDA-MB-231 and -435 breast cancer xenograft models.

223 a panel of six human patient derived ovarian cancer xenograft models.

224 ination with DDR inhibitors in human ovarian cancer xenograft models.

225 says, and in subcutaneous colon and melanoma cancers xenografts models, suggests that demycarosyl-3D-

226 Using endometrial cancer xenografts, modulation of EMP2 expression resulte

227 er cells and growth of HER2+ NCI-N87 gastric cancer xenografts more potently than LJM716 or BYL719 al

228 e-independent growth conditions and a breast cancer xenograft mouse model to assess the impact of nic

229 esulting in an in vivo active (HCT-116 colon cancer xenograft mouse model) anticancer agent.

230 Importantly, in a preclinical gastric cancer xenograft mouse model, drug co-treatments led to

231 In a GPA33-positive human colorectal cancer xenograft mouse model, we validated a SPECT/CT-ba

232 died by using an orthotopic human pancreatic cancer xenograft mouse model.

233 ial for systemic radiovirotherapy in a liver cancer xenograft mouse model.

234 emonstrated against a triple negative breast cancer xenograft mouse model.

235 ough a survival study in a human HT-29 colon cancer xenograft murine model.

236 -replenishment) was performed in human colon cancer xenografts (n = 38) by using a clinical US system

237 In mice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combinati

238 PSMA(+) PC3 PIP and PSMA(-) PC3 flu prostate cancer xenografts on the upper right and left flanks, re

239 Pancreatic cancer xenografts (PANC-1) in nude mice were treated sys

240 A panel of patient-derived ovarian cancer xenografts (PDX), similar in genetics and chemoth

241 ring low-passage, patient-derived pancreatic cancer xenografts (PDX).

242 le drugs, prevented human liver HK1(-)HK2(+) cancer xenograft progression.

243 d 12 treatment groups in trial on an ovarian cancer xenograft, reproducing current therapeutic option

244 tion trial of PP242 in patient-derived colon cancer xenografts, resistance to PP242-induced inhibitio

245 nockdown of TRIP6 in glioblastoma or ovarian cancer xenografts restores nuclear p27(KIP1) expression

246 s antiangiogenic effects in a human prostate cancer xenograft, restoring tumor-dependent vessel growt

247 ly target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing m

248 MDA-MB-231 breast cancer and FaDu head neck cancer xenografts show different pO(2) responses during

249 y targets p5365-73 peptide-expressing breast cancer xenografts, significantly inhibiting tumor growth

250 or uptake in nude mice bearing HeLa cervical cancer xenografts than nontargeted nanoparticles followi

251 screening in vivo on a novel human prostate cancer xenograft that is androgen-independent and induce

252 k of transplantable patient-derived prostate cancer xenografts that capture the biologic and molecula

253 ort spontaneous metastasis of human prostate cancer xenografts that express high levels of galectin-4

254 r-initiating cells in triple-negative breast cancer xenografts that rely on LEFTY1 for growth.

255 ndrogen-independent (CWR22R) human prostatic cancer xenografts, the acute response of CWR22 tumors to

256 erating intratumoral hypoxia in human breast cancer xenografts, the antiangiogenic agents sunitinib a

257 in vitro and its inhibition of s.c. prostate cancer xenografts, the Hsp90 inhibitor 17-AAG stimulates

258 metastatic effects in mouse models of breast cancer xenografts, the reduced expression of proteins in

259 was found (R(2) = 0.73; P < 0.0001) across 3 cancer xenografts, thus providing a strong argument for

260 trix transducer to monitor response of colon cancer xenografts to antiangiogenic therapy with functio

261 the muscle of mice-bearing human pancreatic cancer xenografts to provide noninvasive live imaging of

262 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prol

263 y and the therapeutic response of pancreatic cancer xenografts treated with a vaccinia virus carrying

264 homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in pro

265 formin administration on non-small cell lung cancer xenograft tumor hypoxia using PET imaging with th

266 rofiles in a set of patient-derived prostate cancer xenograft tumor lines, we identified miR-100-5p a

267 ion of tumor angiogenesis in a human ovarian cancer xenograft tumor model in mice.

268 served similar synergistic effects in a lung cancer xenograft tumor model.

269 n contrast, DIM did not protect human breast cancer xenograft tumors against radiation under the cond

270 levels retard, the growth of human prostate cancer xenograft tumors in mice.

271 y of fractionated radiation therapy in human cancer xenograft tumors in nude rats without increased t

272 ta-catenin sensitizes triple-negative breast cancer xenograft tumors to chemotherapeutics and reduces

273 Moreover, the volumes of prostate cancer xenograft tumors with knockdown of hCtr1 (179 +/-

274 knockdown reduces growth of lung and breast cancer xenograft tumors.

275 related peptidase 2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either m

276 ide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derive

277 vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule.

278 excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR s

279 Pa, the amount of nanoparticles deposited in cancer xenografts was increased from 4- to 14-fold, and

280 , in luciferase MDA-MB-231-Luc-D3H2LN breast cancer xenografts was shown.

281 in NSG mice harboring orthotopic pancreatic cancer xenografts, we assessed CSC viability, CSC freque

282 glutamine in mice bearing subcutaneous colon cancer xenografts, we showed substantial amounts of infu

283 e the effects of EF24 in vivo, HCT-116 colon cancer xenografts were established in nude mice and EF24

284 Finally, orthotopic breast cancer xenografts were established in nude mice by injec

285 bearing established Capan-1 human pancreatic cancer xenografts were given TF10 and then received the

286 Mice bearing orthotopic MDA-MB-231 breast cancer xenografts were imaged noninvasively during rest

287 SCID mice with human HCT116 cancer xenografts were imaged with (99m)Tc-TCP-1 or cont

288 Mice bearing subcutaneous prostate cancer xenografts were injected with 0.74-18.5 MBq of th

289 d Methods Twenty-three mice with human colon cancer xenografts were randomized to receive either sing

290 e bearing subcutaneously implanted H460 lung cancer xenografts were treated with a novel vascular dis

291 In SKOV-3ip1 ovarian cancer xenografts, which express high levels of alpha(5)

292 st human androgen receptor-negative prostate cancer xenografts whose cells induced an osteoblastic re

293 Treatment of mice bearing a colon cancer xenograft with the antibiotic metronidazole reduc

294 Treatment of pre-established human oral cancer xenografts with a BMI1 inhibitor resulted in abro

295 Treatment of primary colorectal cancer xenografts with a small-molecule BMI-1 inhibitor

296 Pretreatment of mice bearing prostate cancer xenografts with acriflavine prevented tumor growt

297 nude mice bearing subcutaneous human breast cancer xenografts with different levels of HER2 expressi

298 Human prostate cancer xenografts with increased (64)Cu radioactivity we

299 the response to trastuzumab in BT474 breast cancer xenografts with N-[2-(4-(18)F-fluorobenzamido)eth

300 Treatment of mice bearing breast cancer xenografts with the inhibitory antibodies resulte